Harrow has re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy for vernal keratoconjunctivitis (VKC), a serious allergic eye disease primarily affecting children. The re-launch includes a comprehensive commercial strategy focused on physician education, patient access and affordability initiatives. VERKAZIA is a calcineurin inhibitor immunomodulator that targets VKC's underlying inflammatory mechanisms and may reduce the need for steroid rescue, which carries risks including glaucoma or cataract formation. VKC can lead to sight-threatening conditions if left untreated. Chief Executive Officer Mark Baum said the re-launch aims to ensure dependable supply and remove access barriers for this evidence-based, steroid-sparing treatment. VERKAZIA represents the second of three priority products in Harrow's portfolio currently being executed.

Harrow, Inc. (NASDAQ:HROW) had its price target reduced to $60 from $65 by B.Riley on 14 May, though the firm maintained its Buy rating. The adjustment followed first-quarter results impacted by weaker pricing for VEVYE and lowered near-term growth expectations. The Nashville-based ophthalmic pharmaceutical company reported first-quarter revenue of $44.2 million, including an $8 million non-recurring adjustment related to VEVYE commercial coverage. Despite pricing pressures, the company highlighted record VEVYE prescriptions and strong performance from IHEEZO and TRIESENCE, with unit demand rising 18% and doubling respectively year over year. Harrow reaffirmed full-year revenue guidance of $350–$365 million. B.Riley cited upcoming product launches, reimbursement coding catalysts and expanding commercial leverage as factors supporting stronger second-half performance.

Harrow Inc reported Q1 2026 revenue of $44.2 million and negative adjusted EBITDA of $12.7 million, whilst reaffirming full-year revenue guidance of $350 million to $365 million. The company expects Q2 revenue between $71 million and $81 million. VEVYE generated $20.9 million in revenue, with new prescriptions growing approximately 25% sequentially and market share reaching 14%. The company doubled its sales force by hiring over 90 professionals. TRIESENCE unit volume surged 136% year-over-year. However, the company faced an $8 million revenue reduction due to VEVYE coverage modelling issues. IHEEZO contributed just $1.9 million as channel inventory absorbed demand. High-deductible patient challenges also impacted net pricing, requiring business rule adjustments in mid-April.